Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada
- PMID: 35621649
- PMCID: PMC9140092
- DOI: 10.3390/curroncol29050259
Wait Times and Survival in Lung Cancer Patients across the Province of Quebec, Canada
Abstract
Lung cancer is the leading cause of cancer death worldwide, with a five-year survival of 22% in Canada. Guidelines recommend rapid evaluation of patients with suspected lung cancer, but the impact on survival remains unclear. We reviewed medical records of all patients with newly diagnosed lung cancer in four hospital networks across the province of Quebec, Canada, between 1 February and 30 April 2017. Patients were followed for 3 years. Wait times for diagnosis and treatment were collected, and survival analysis using a Cox regression model was conducted. We included 1309 patients, of whom 39% had stage IV non-small cell lung cancer (NSCLC). Median wait times were, in general, significantly shorter in patients with stage III-IV NSCLC or SCLC. Surgery was associated with delays compared to other types of treatments. Median survival was 12.9 (11.1-15.7) months. The multivariate survival model included age, female sex, performance status, histology and stage, treatment, and the time interval between diagnosis and treatment. Longer wait times had a slightly protective to neutral effect on survival, but this was not significant in the stage I-II NSCLC subgroup. Wait times for the diagnosis and treatment of lung cancer were generally within targets. The shorter wait times observed for advanced NSCLC and SCLC might indicate a tendency for clinicians to act quicker on sicker patients. This study did not demonstrate the detrimental effect of longer wait times on survival.
Keywords: delays; non-small cell lung cancer; overall survival; small cell lung cancer; timeliness; wait times.
Conflict of interest statement
Catherine Labbé has received honoraria from AstraZeneca, Brystol-Myers Squibb, Merck, Pfizer, and Roche. She has also received payment for expert testimony from Roche and Pfizer. She has also been on advisory boards for Amgen, Pfizer, Roche, AstraZeneca, Brystol-Myers Squibb, Sanofi Genzyme, Jazz Pharmaceuticals, LEO Pharma, and Merck. Philippe Joubert has received grants from AstraZeneca, Biomark Diagnostic Signature, and Imagia. He has also received honoraria from AstraZeneca. Marie-Hélène Denault, Carolle Saint-Pierre, Brigitte Fournier, Andréanne Gagné, Claudia Morillon, Serge Simard, and Simon Martel do not have any interests to declare.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9140092/bin/curroncol-29-00259-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9140092/bin/curroncol-29-00259-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9140092/bin/curroncol-29-00259-g003.gif)
Similar articles
-
Waiting times in early-stage non-small cell lung cancer (NSCLC).J Thorac Oncol. 2008 Aug;3(8):865-70. doi: 10.1097/JTO.0b013e318180210c. J Thorac Oncol. 2008. PMID: 18670304
-
Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study.Lung Cancer. 2024 Aug;194:107867. doi: 10.1016/j.lungcan.2024.107867. Epub 2024 Jun 30. Lung Cancer. 2024. PMID: 39047614
-
Evaluation of a 'Watch and Wait' Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population.Clin Oncol (R Coll Radiol). 2015 Sep;27(9):505-13. doi: 10.1016/j.clon.2015.05.009. Epub 2015 Jun 19. Clin Oncol (R Coll Radiol). 2015. PMID: 26095646
-
Nunavimmi puvakkut kaggutimik aanniaqarniq: Qanuilirqitaa? Lung cancer in Nunavik: How are we doing? A retrospective matched cohort study.CMAJ. 2024 Feb 19;196(6):E177-E186. doi: 10.1503/cmaj.230682. CMAJ. 2024. PMID: 38378218 Free PMC article. Review.
-
Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature.Can J Urol. 2006 Jun;13 Suppl 3:30-6. Can J Urol. 2006. PMID: 16818010 Review.
Cited by
-
Marital status impacts survival of stage I non-small-cell lung cancer: a propensity-score matching analysis.Future Sci OA. 2024 May 15;10(1):FSO926. doi: 10.2144/fsoa-2023-0103. eCollection 2024. Future Sci OA. 2024. PMID: 38827800 Free PMC article.
-
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.Curr Oncol. 2023 Jul 8;30(7):6559-6574. doi: 10.3390/curroncol30070481. Curr Oncol. 2023. PMID: 37504341 Free PMC article.
-
Inequalities in survival and care across social determinants of health in a cohort of advanced lung cancer patients in Quebec (Canada): A high-resolution population-level analysis.Cancer Med. 2023 Jun;12(11):12683-12704. doi: 10.1002/cam4.5897. Epub 2023 Apr 5. Cancer Med. 2023. PMID: 37017510 Free PMC article.
References
-
- Noone A.M., Howlader N., Krapcho M., Miller D., Brest A., Yu M., Ruhl J., Tatalovich Z., Mariotto A., Lewis D.R., et al., editors. SEER Cancer Statistics Review 1975–2015. National Cancer Institute; Bethesda, MD, USA: 2018. [(accessed on 21 March 2021)]. Available online: https://seer.cancer.gov/csr/1975_2015/
-
- Ellison L.F. Progress in net cancer survival in Canada over 20 years. Health Rep. 2018;29:10–18. - PubMed
-
- Canadian Cancer Statistics Advisory Committee. Statistics Canada and the Public Health Agency of Canada (CCS) Canadian Cancer Statistics 2021; Canadian Cancer Statistics Advisory Committee. 2021. [(accessed on 7 November 2021)]. Available online: https://cdn.cancer.ca/-/media/files/research/cancer-statistics/2021-stat....
-
- Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J. Natl. Cancer Inst. 1980;65:25–32. - PubMed
-
- Blackstock A.W., Herndon J.E., Paskett E.D., Perry M.C., Graziano S.L., Muscato J.J., Kosty M.P., Akerley W.L., Holland J., Fleishman S. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. J. Natl. Cancer Inst. 2002;94:284–290. doi: 10.1093/jnci/94.4.284. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous